Free Trial

Trevena (TRVN) Competitors

Trevena logo
$0.97 +0.06 (+6.59%)
As of 07/9/2025 02:23 PM Eastern

TRVN vs. LIPO, PALI, ONVO, ADIL, WINT, GENE, EVAX, PPBT, ZVSA, and ENVB

Should you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Lipella Pharmaceuticals (LIPO), Palisade Bio (PALI), Organovo (ONVO), Adial Pharmaceuticals (ADIL), Windtree Therapeutics (WINT), Genetic Technologies (GENE), Evaxion A/S (EVAX), Purple Biotech (PPBT), ZyVersa Therapeutics (ZVSA), and Enveric Biosciences (ENVB). These companies are all part of the "pharmaceutical products" industry.

Trevena vs. Its Competitors

Lipella Pharmaceuticals (NASDAQ:LIPO) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lipella Pharmaceuticals has higher revenue and earnings than Trevena. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipella Pharmaceuticals$536.36K6.82-$5.02M-$4.08-0.20
Trevena$443K2.10-$40.29M-$47.04-0.02

Trevena has a consensus price target of $5.00, suggesting a potential upside of 415.46%. Given Trevena's stronger consensus rating and higher possible upside, analysts plainly believe Trevena is more favorable than Lipella Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipella Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Trevena
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Trevena has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Trevena's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals-988.83% -224.08% -172.88%
Trevena N/A N/A -119.55%

In the previous week, Trevena had 1 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Lipella Pharmaceuticals. Trevena's average media sentiment score of 1.08 beat Lipella Pharmaceuticals' score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Trevena Positive

Lipella Pharmaceuticals has a beta of -0.08, suggesting that its stock price is 108% less volatile than the S&P 500. Comparatively, Trevena has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.

Summary

Trevena beats Lipella Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVN vs. The Competition

MetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$930K$790.61M$5.55B$8.99B
Dividend YieldN/A4.84%5.25%4.03%
P/E Ratio-0.021.3027.4420.13
Price / Sales2.10227.12414.93172.83
Price / CashN/A23.4437.0657.97
Price / Book-0.096.148.135.61
Net Income-$40.29M-$27.58M$3.16B$248.50M
7 Day Performance3.19%0.99%2.92%4.36%
1 Month Performance-3.96%7.42%3.14%6.87%
1 Year Performance-82.72%7.17%33.91%20.78%

Trevena Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVN
Trevena
2.4594 of 5 stars
$0.97
+6.6%
$5.00
+415.5%
-82.0%$930K$443K-0.0240Gap Down
LIPO
Lipella Pharmaceuticals
1.5052 of 5 stars
$0.85
+9.1%
N/A-76.7%$3.49M$536.36K-0.214
PALI
Palisade Bio
2.2278 of 5 stars
$0.73
+1.2%
$12.00
+1,534.9%
-82.8%$3.48M$250K-0.1110News Coverage
ONVO
Organovo
N/AN/AN/AN/A$3.47M$122K-2.4020Gap Up
ADIL
Adial Pharmaceuticals
2.3743 of 5 stars
$0.33
-0.4%
$8.00
+2,357.0%
-71.5%$3.41MN/A-0.2220News Coverage
Gap Down
WINT
Windtree Therapeutics
1.8325 of 5 stars
$0.80
-14.1%
$350.00
+43,759.6%
-99.6%$3.40MN/A0.0030Gap Down
High Trading Volume
GENE
Genetic Technologies
N/A$0.77
flat
N/AN/A$3.37M$7.66M0.0050High Trading Volume
EVAX
Evaxion A/S
2.3295 of 5 stars
$2.30
-3.8%
$10.00
+334.8%
-84.7%$3.35M$3.34M-1.9860
PPBT
Purple Biotech
1.8799 of 5 stars
$2.44
-1.6%
$33.00
+1,252.5%
N/A$3.30MN/A-0.9320
ZVSA
ZyVersa Therapeutics
1.0634 of 5 stars
$0.66
-1.4%
N/A-86.5%$3.20MN/A0.002News Coverage
ENVB
Enveric Biosciences
2.6031 of 5 stars
$1.27
+0.8%
$10.00
+687.4%
-80.2%$3.11MN/A-0.0320

Related Companies and Tools


This page (NASDAQ:TRVN) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners